TNF-mediated inflammatory disease
- PMID: 18161752
- DOI: 10.1002/path.2287
TNF-mediated inflammatory disease
Abstract
TNF was originally described as a circulating factor that can cause necrosis of tumours, but has since been identified as a key regulator of the inflammatory response. This review describes the known signalling pathways and cell biological effects of TNF, and our understanding of the role of TNF in human disease. TNF interacts with two different receptors, designated TNFR1 and TNFR2, which are differentially expressed on cells and tissues and initiate both distinct and overlapping signal transduction pathways. These diverse signalling cascades lead to a range of cellular responses, which include cell death, survival, differentiation, proliferation and migration. Vascular endothelial cells respond to TNF by undergoing a number of pro-inflammatory changes, which increase leukocyte adhesion, transendothelial migration and vascular leak and promote thrombosis. The central role of TNF in inflammation has been demonstrated by the ability of agents that block the action of TNF to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. The increased incidence of infection in patients receiving anti-TNF treatment has highlighted the physiological role of TNF in infectious diseases.
2007 Pathological Society of Great Britain and Ireland
Similar articles
-
A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.J Immunother. 2008 Apr;31(3):225-34. doi: 10.1097/CJI.0b013e31816a88f9. J Immunother. 2008. PMID: 18317365
-
Mechanisms for modulating TNF alpha in immune and inflammatory disease.Curr Opin Drug Discov Devel. 2001 Sep;4(5):635-50. Curr Opin Drug Discov Devel. 2001. PMID: 12825458 Review.
-
Tumour necrosis factor in infectious disease.J Pathol. 2013 Jun;230(2):132-47. doi: 10.1002/path.4187. J Pathol. 2013. PMID: 23460469 Review.
-
Tumour necrosis factor inhibitors in ankylosing spondylitis.Intern Med J. 2008 Oct;38(10):781-9. doi: 10.1111/j.1445-5994.2008.01639.x. Epub 2008 Apr 14. Intern Med J. 2008. PMID: 18422565 Review.
-
Tumor necrosis factor and anti-tumor necrosis factor therapies.J Rheumatol Suppl. 2010 May;85:27-39. doi: 10.3899/jrheum.091463. J Rheumatol Suppl. 2010. PMID: 20436163 Review.
Cited by
-
Zeolitic Imidazolate Framework-8 Offers an Anti-Inflammatory and Antifungal Method in the Treatment of Aspergillus Fungal Keratitis in vitro and in vivo.Int J Nanomedicine. 2024 Nov 1;19:11163-11179. doi: 10.2147/IJN.S480800. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39502641 Free PMC article.
-
TNF Production and Release from Microglia via Extracellular Vesicles: Impact on Brain Functions.Cells. 2020 Sep 23;9(10):2145. doi: 10.3390/cells9102145. Cells. 2020. PMID: 32977412 Free PMC article. Review.
-
Expression of tumor necrosis factor-alpha-mediated genes predicts recurrence-free survival in lung cancer.PLoS One. 2014 Dec 30;9(12):e115945. doi: 10.1371/journal.pone.0115945. eCollection 2014. PLoS One. 2014. PMID: 25548907 Free PMC article.
-
Recognition of human tumor necrosis factor α (TNF-α) by therapeutic antibody fragment: energetics and structural features.J Biol Chem. 2012 Mar 9;287(11):8613-20. doi: 10.1074/jbc.M111.318451. Epub 2012 Jan 19. J Biol Chem. 2012. PMID: 22262846 Free PMC article.
-
Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.Clin Exp Immunol. 2012 Aug;169(2):100-8. doi: 10.1111/j.1365-2249.2012.04596.x. Clin Exp Immunol. 2012. PMID: 22774984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials